Presentations Highlight New Data on Diagnostic Accuracy and Novel Biomarkers of Disease Severity in Multiple System AtrophyMELBOURNE, Australia and SAN...
ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the...
GOTHENBURG, SE / ACCESSWIRE / August 21, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for...
GOTHENBURG, SE / ACCESSWIRE / August 21, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for...
LGR5 is expressed, both in vitro and in vivo, by numerous human cancers, including colorectal, ovarian, gastric, brain, and pancreatic...
Acquisition of Bird Rock Bio builds Skye's position as a leading endocannabinoid system-focused pharmaceutical companyNew capital funds anticipated Phase 2a...
Mississauga, Ontario--(Newsfile Corp. - August 17, 2023) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging force in...
Committed to revitalize the age-old treatment technique, Ipswich Spine embodies a patient-centric strategy.SUFFOLK, UK / ACCESSWIRE / August 17, 2023...
Biostat STR(R) Bioreactor Biostat STR® now contains a fully compatible embedded XCell® ATF hardware and software moduleBioreactor and cell retention...
Jaguar Health family company Napo Pharmaceuticals focuses on essential supportive care and management of neglected toxicities in multiple complicated disease...
NEWTOWN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with...
Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment MarketTORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma...
CARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company...
The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials...
- AB126 is an unmodified exosome derived from neural stem cells with the innate ability to cross the blood-brain-barrier and...
LAS VEGAS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Dr. Jack Jacobs, Chief Science Officer of Zhittya Genesis Medicine, Inc. (a...
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or...
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to...
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical...